These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6418341)

  • 1. [Persistence of immunity to attenuated measles live vaccine. V. Persistence of immunity after primary immunization with 4 strains of live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1983 Aug; 63(8):490-2. PubMed ID: 6418341
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on the persistence of immunity 14-15 years after vaccination with a live measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):389-91. PubMed ID: 2598095
    [No Abstract]   [Full Text] [Related]  

  • 3. [Persistence of immunity to attenuated measles live vaccine. VI. Observation on the results of revaccination with different vaccines via varied routes].
    Zhonghua Yi Xue Za Zhi; 1983 Sep; 63(9):541-5. PubMed ID: 6418355
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Duration of the immunity of attenuated measles vaccine. IV. Result of a 9-year observation following primary inoculation].
    Zhonghua Yi Xue Za Zhi; 1983 Jul; 63(7):423-5. PubMed ID: 6416645
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical reactogenicity and immunogenicity of five live measles vaccine strains.
    Chin Med J (Engl); 1981 Apr; 94(4):201-6. PubMed ID: 6790234
    [No Abstract]   [Full Text] [Related]  

  • 7. An extremely attenuated, live measles virus vaccine (CAM-EX). Persistence of low titer-antibody in institutionalized children with psychomotor retardation after vaccination.
    Ueda K; Hashiguchi K; Nakashima F; Ueda S; Takahashi M
    Biken J; 1981 Sep; 24(3):119-22. PubMed ID: 7337678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of measles vaccines in Japan.
    Ueda S
    Vaccine; 2009 May; 27(24):3230-1. PubMed ID: 19446197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Means of improving measles vaccinal prophylaxis].
    Smorodintsev AA; Boĭchuk LM; Rykushin IuP; Smorodintsev AA
    Tr Inst Im Pastera; 1979; 53():12-9. PubMed ID: 162456
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
    Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
    Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and serological studies with a live further attenuated measles vaccine (Moraten) in Chile].
    Ristori C; Boccardo H; Borgoño JM; Greiber R; Heras E; Carrillo B; Solari G; Concha F
    Rev Med Chil; 1970 Jan; 98(1):42-5. PubMed ID: 4157374
    [No Abstract]   [Full Text] [Related]  

  • 12. Sero-conversion response to Mevilin-L measles vaccine at age 6-15 months.
    Katiyar GP; Kaur G; Agarwal DK; Gulati AK; Kalra A; Agarwal KN
    Indian Pediatr; 1985 Sep; 22(9):653-9. PubMed ID: 3833785
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and serological evaluation of live measles vaccine in India.
    Phadke MA; Rodrigues JJ; Mehta JM; Ayachit V
    Indian Pediatr; 1983 Aug; 20(8):573-6. PubMed ID: 6662582
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies on the persistence of immunity 15 years after revaccination with measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):392-5. PubMed ID: 2598096
    [No Abstract]   [Full Text] [Related]  

  • 15. Serological survey of measles immunization with the Rimevax--RIT--vaccine in a Romanian district.
    Ciufecu E; Dincă L; Serbănescu R; Dinculescu M; Găleşanu M
    Arch Roum Pathol Exp Microbiol; 1980; 39(1):31-40. PubMed ID: 6996640
    [No Abstract]   [Full Text] [Related]  

  • 16. [Measles immunization and its problems].
    Kökkaya A
    Mikrobiyol Bul; 1982 Jan; 16(1):66-70. PubMed ID: 7144618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The cell-mediated response after measles vaccination].
    Pala S; Crimaldi G; Consolini R; Macchia P
    Pediatr Med Chir; 1998; 20(3):213-6. PubMed ID: 9744016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The perilous path to a better measles vaccine.
    Minor PD
    CVI Forum; 1992 Oct; (2):8-10. PubMed ID: 12321775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
    Nkrumah FK; Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA
    Bull World Health Organ; 1998; 76(4):353-9. PubMed ID: 9803586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles immunity in HIV-infected children.
    Walter EB; Katz SL; Bellini WJ
    Pediatr AIDS HIV Infect; 1994 Oct; 5(5):300-4. PubMed ID: 11361371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.